Idera Pharmaceuticals, Inc. News Releases http://ir.iderapharma.com/ Idera Pharmaceuticals, Inc. News Releases en Idera Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update http://ir.iderapharma.com/news-releases/news-release-details/idera-pharmaceuticals-reports-first-quarter-2019-financial EXTON, Pa. , May 02, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease indications, today Thu, 02 May 2019 16:30:00 -0400 Idera Pharmaceuticals, Inc. News Releases 15716 Idera Pharmaceuticals Provides Corporate Update http://ir.iderapharma.com/news-releases/news-release-details/idera-pharmaceuticals-provides-corporate-update EXTON, Pa. , April 10, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drugs for both oncology and rare disease indications, today announced Wed, 10 Apr 2019 07:00:00 -0400 Idera Pharmaceuticals, Inc. News Releases 15646 Idera Pharmaceuticals Presents ILLUMINATE-101 Data Demonstrating Tilsotolimod Activates Innate and Adaptive Immunity as Monotherapy in Patients with Refractory Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting http://ir.iderapharma.com/news-releases/news-release-details/idera-pharmaceuticals-presents-illuminate-101-data-demonstrating – Tilsotolimod activated IFN-α and MHC class II genes in the tumor microenvironment across multiple tumor types – EXTON, Pa. , April 02, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and Tue, 02 Apr 2019 07:00:00 -0400 Idera Pharmaceuticals, Inc. News Releases 15626 Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update http://ir.iderapharma.com/news-releases/news-release-details/idera-pharmaceuticals-reports-fourth-quarter-and-year-end-2018 – ILLUMINATE-301 Enrollment on Track for Completion Q4 2019 – – ILLUMINATE-204 Enrollment Complete; Data Anticipated Q4 2019  – – ILLUMINATE-206 Trial Expected to Initiate Q2 2019 – – Chief Medical Officer Dr. Joanna Horobin Announces Retirement Plan – – Company to Present at Barclays Global Wed, 06 Mar 2019 16:30:00 -0500 Idera Pharmaceuticals, Inc. News Releases 15606 Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment http://ir.iderapharma.com/news-releases/news-release-details/idera-pharmaceuticals-completes-enrollment-illuminate-204-trial - Results from the Phase 2 Expansion of ILLUMINATE-204 anticipated to be reported in the 4 th Quarter of 2019 –   - December 2018 Interim Update of 34 efficacy evaluable patients demonstrated 32.4% achieved partial response (PR) or better; 76.5% of patients achieved disease control - EXTON, Pa. Wed, 27 Feb 2019 07:00:00 -0500 Idera Pharmaceuticals, Inc. News Releases 15581 Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference http://ir.iderapharma.com/news-releases/news-release-details/idera-pharmaceuticals-present-37th-annual-jp-morgan-healthcare EXTON, Pa. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the 37 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:30 a.m. Pacific Time ( 11:30 a.m. Eastern Time ) at the Westin St. Fri, 04 Jan 2019 07:30:00 -0500 Idera Pharmaceuticals, Inc. News Releases 15521 Idera Pharmaceuticals Announces Appointment of Carol A. Schafer to its Board of Directors http://ir.iderapharma.com/news-releases/news-release-details/idera-pharmaceuticals-announces-appointment-carol-schafer-its EXTON, Pa. , Dec. 18, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that Carol A. Schafer joined its Board of Directors, effective December 18 , 2018.  Ms. Schafer is a seasoned financial professional with more than 25 years of experience in investment banking Tue, 18 Dec 2018 16:05:00 -0500 Idera Pharmaceuticals, Inc. News Releases 15471 Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment http://ir.iderapharma.com/news-releases/news-release-details/idera-pharmaceuticals-presents-clinical-safety-and-efficacy - 32.4% of patients evaluable for efficacy achieved partial response or better; 76.5% of patients achieved disease control -   - Tumor shrinkage observed in both injected and uninjected lesions, indicating an abscopal effect - EXTON, Pa. , Dec. 14, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Fri, 14 Dec 2018 07:00:00 -0500 Idera Pharmaceuticals, Inc. News Releases 15461 Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018 http://ir.iderapharma.com/news-releases/news-release-details/idera-pharmaceuticals-provide-illuminate-204-clinical-data EXTON, Pa. , Dec. 12, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined Wed, 12 Dec 2018 16:01:00 -0500 Idera Pharmaceuticals, Inc. News Releases 15446 Idera Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update http://ir.iderapharma.com/news-releases/news-release-details/idera-pharmaceuticals-reports-third-quarter-2018-financial –  Company to Provide ILLUMINATE 204 Data Update in the First Half of December 2018 – –  Cash runway into first quarter of 2020 – EXTON, Pa. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and Tue, 06 Nov 2018 16:30:00 -0500 Idera Pharmaceuticals, Inc. News Releases 15421